Catalog
Melanocortin receptor agonist (MC1R/MC3R/MC4R)

PT-141 (Bremelanotide)

aka Vyleesi

FDA-approved for HSDD in premenopausal women; widely misused off-label for ED.

FDA-approvedGrade B — Supported, context-specific
Target
MC4R primarily

Mechanism of action

Synthetic α-MSH analog. Acts on central melanocortin pathways modulating sexual desire — mechanism distinct from PDE5i.

Pharmacokinetics

SC, on-demand. t½ ~2 h.

Clinical context

HSDD in premenopausal women.

Dosing
1.75 mg SC ≥45 min before anticipated activity. Max 1 dose/24 h, ≤8/month.

Monitoring

  • Blood pressure post-dose (transient rise)

Safety

Contraindications
  • Uncontrolled hypertension
  • Established CV disease
Adverse effects
  • Nausea (~40%)
  • Flushing, headache
  • Transient BP elevation
  • Focal hyperpigmentation with chronic use

Covered in modules

Module 09
Melanocortins: PT-141 & Melanotan
Sex, tan, and centrally acting agonists.

Related compounds

Non-selective melanocortin receptor agonist
Melanotan II

Generate prescriber-grade deep dive

Pull in expanded mechanism, PK/PD, dosing strategies for special populations, drug interactions, monitoring cadence, head-to-head differentials, prescriber pearls, and patient FAQs for PT-141 (Bremelanotide).

Educational reference. Not medical advice. Always verify against current FDA labeling and local regulatory guidance before prescribing or counseling.